CClinicalTrials.gg
CompletedNCT03284944Updated Sep 17, 2020

Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS)

An observational study in Blood Loss Anemia, sponsored by Population Health Research Institute. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-17.

Sponsored by Population Health Research Institute · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
369
Ages
18 Years and older
Sex
All
01

Study summary

STRATUS will evaluate the use of small-volume ("soft-draw") blood collection tubes for laboratory testing in reducing anemia and transfusion in intensive care unit patients without significant adverse consequences. This is a simple, cost-neutral intervention that could improve the quality of patient care and reduce the harms of frequent laboratory testing.

Read the detailed description

The STRATUS Pilot Study is a prospective observational study (before-after design) to assess the feasibility of implementing a full-scale randomized trial powered for clinical outcomes (RBC transfusion, incidence and severity of anemia). Identification of barriers and facilitators of implementation will enhance the conduct of the full-scale trial and facilitate incorporation of the intervention into routine practice.

02

Conditions studied

  • Blood Loss Anemia

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients admitted to the participating intensive care unit at the investigative site.

Eligibility criteria

Investigative Site Eligibility:

  • Intensive care unit with at least 15 beds with capacity for mechanical ventilation
  • Current standard to use standard-draw blood collection tubes
  • Availability of hospital administrative data and electronic patient information
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
369 participants (actual)
Patient registry
No

Groups and cohorts

  • Control (Before) Period

    Use of standard-volume blood collection tubes (6 weeks)

    Device: Standard-Volume

  • Intervention (After) Period

    Use of small-volume ("soft-draw") blood collection tubes (6 weeks following 2-week washout period)

    Device: Small-Volume

Interventions

  • DeviceSmall-Volume

    Small-volume (2 - 3 mL "soft-draw" Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.

  • DeviceStandard-Volume

    Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.

05

What researchers measure

Primary outcomes

  1. Successful crossover from standard-volume to small-volume tubes

    Defined as at least 95% correct tubes collected during an audit of tubes in the storage area at the end of the washout period

    Time frame: 2 week washout period

  2. Adherence to the correct tube size during the intervention period

    Defined as at least 95% adherence to allocated tube size evaluated during audits of tubes in the storage area

    Time frame: 6 week intervention period

  3. Sufficient volume for testing with small-volume tubes

    Defined as \<3% of samples reported as inadequate volume for testing

    Time frame: 6 week intervention period

  4. Acceptability of the intervention by end-users

    Acceptability qualitatively evaluated during structured focus group discussions

    Time frame: 6 week intervention period

  5. Complete primary data collection

    Defined as at least 95% of patients with complete data collected

    Time frame: 14 weeks

Secondary outcomes

  1. Reduction in blood loss

    Reduction in blood loss from routine hematology, chemistry, and coagulation testing using small-volume tubes.

    Time frame: 12 weeks

  2. RBC units transfused

    Number of RBC units transfused per patient-day in the ICU.

    Time frame: 12 weeks

  3. Change in hemoglobin

    Change in hemoglobin level from ICU admission to ICU discharge (or death) adjusted for RBC transfusion.

    Time frame: 12 weeks

  4. ICU and hospital length of stay

    ICU and hospital length of stay

    Time frame: 12 weeks

  5. ICU and hospital mortality

    ICU and in-hospital mortality

    Time frame: 12 weeks

06

Study locations

1 site
  • Hamilton Health Sciences - Hamilton General Hospital
    Hamilton, Ontario L8L2X2, Canada
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03284944
Lead sponsor
Population Health Research Institute
Responsible party
Sponsor
First posted
Sep 15, 2017
Start date
Nov 1, 2017
Primary completion
Feb 7, 2018
Completion
Dec 1, 2018
Last update
Sep 17, 2020

Study contacts

Deborah Siegal, MD
principal investigator · Population Health Research Institute, McMaster University, Hamilton Health Sciences
Stuart Connolly, MD
principal investigator · Population Health Research Institute, McMaster University, Hamilton Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion